Evid Invest

Fair value · GENMAB A/S (GMAB) · updated 2026-10-03 · from 20-F FY2025

GENMAB A/S trades at $34.81. We are not reading assumptions out of that price: financials are filed in DKK; our prices are in USD, so these methods need a conversion we do not yet publish.

Everything below is unaffected: the filed statements, the filing they came from, and GMAB’s growth history are all as reported.

The filing behind these numbers

GENMAB A/S
Revenue
DKK 3.7B
Diluted EPS
DKK 1.54
Free cash flow
DKK 1.1B
operating cash flow − capital expenditure
Diluted shares
62.7M
weighted average

20-F FY2025 · fiscal year ended 2025-12-31 · filed 2026-02-17 · accession 0001434265-26-000014

Open this filing on sec.gov
EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.